An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

June 20, 2012

Primary Completion Date

July 13, 2015

Study Completion Date

April 28, 2017

Conditions
Granulomatosis With PolyangiitisMicroscopic Polyangiitis
Interventions
DRUG

Rituximab

Participants received rituximab at the discretion of their treating physicians.

Trial Locations (15)

10065

Weill Medical College of Cornell University; Hospital for Special Surgery, New York

15261

University of Pittsburgh, Pittsburgh

19104

University of Pennsylvania, Philadelphia

21224

Johns Hopkins Asthma&Allergy, Baltimore

27516

UNC- Chapel Hill, Chapel Hill

27710

Duke Univ Medical Center, Durham

32224

Mayo Clinic, Jacksonville

44915

Cleveland Clinic Foundation, Cleveland

55905

Mayo Clinic Rochester; Int.Med - Div. of Pul, Rochester

60612

Rush University Medical Center, Chicago

84132

University of Utah; Division of Rheumatology, Salt Lake City

85025

Mayo Clinic Arizona, Scottsdale

90048

Cedars-Sinai Medical Center, Los Angeles

02114

Mass. General Hospital, Boston

02118-2393

Boston Medical Center, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY